# Christin Glorioso

> Christin Glorioso, MD, PhD, is a physician-scientist and serial entrepreneur who is CEO and co-founder of NeuroAge Therapeutics, a San Francisco brain-health company building AI-powered 'aging clocks' for the human brain. Trained at MIT and the Carnegie Mellon/University of Pittsburgh Medical Scientist Training Program, she spent two decades studying how brains age before leaving academia to turn that research into a diagnostic and drug-development engine. NeuroAge combines MRI brain-volume data, cognitive testing and proprietary RNA blood biomarkers - validated on data from more than 500,000 people - to estimate brain age and dementia risk decades before symptoms. She also founded the nonprofit Longevity Global and led the world's top-ranked US COVID-19 forecasting model in the XPRIZE Pandemic Response Challenge.

- **Role:** CEO and Co-founder at NeuroAge Therapeutics
- **Organizations:** NeuroAge Therapeutics, Longevity Global, Academics for the Future of Science, MIT, UCSF Bakar Aging Research Institute, TeachAids
- **Nationality:** American
- **Education:** BS, Cell and Molecular Biology, University of Michigan, MD and PhD in Neuroscience, University of Pittsburgh School of Medicine / Carnegie Mellon (MSTP), Postdoctoral Associate, Computational Biology, MIT
- **Known for:** Founded and leads NeuroAge Therapeutics, a longevity tech-bio company built on 20+ years of brain-aging research, Pioneered 'aging clocks' for the human brain using RNA biomarkers, MRI and cognitive data from 500,000+ people, Author of 30+ peer-reviewed publications

## Career timeline

- **2002** — Earned BS in Cell and Molecular Biology at the University of Michigan
- **2011** — Completed MD/PhD via the CMU/Pitt Medical Scientist Training Program; thesis on the genetics and molecular pathways of CNS aging
- **2012** — Began postdoctoral research in computational biology at MIT
- **2013** — Co-founded the nonprofit Academics for the Future of Science
- **2017** — Became a research scientist at MIT, pioneering aging clocks for the human brain
- **2021** — Served as Chief Strategist of UCSF's Bakar Aging Research Institute and Head of AI at TeachAids
- **2021** — Led a global research collective whose model ranked #1 in the US in the XPRIZE Pandemic Response Challenge
- **2022** — Founded NeuroAge Therapeutics; won the US National Institute on Aging Startup Challenge
- **2023** — NeuroAge named a top-10 company to watch by Life Science Nation
- **2026** — NeuroAge raised seed funding and expanded its brain-aging test offerings

## Achievements

- Founded and leads NeuroAge Therapeutics, a longevity tech-bio company built on 20+ years of brain-aging research
- Pioneered 'aging clocks' for the human brain using RNA biomarkers, MRI and cognitive data from 500,000+ people
- Author of 30+ peer-reviewed publications
- Led the #1 US COVID-19 predictive model out of 104 global teams in the XPRIZE Pandemic Response Challenge (7% error rate)
- Won the US National Institute on Aging Startup Challenge 2022
- Named a top-10 company to watch in 2023 by Life Science Nation
- Received the MIT Infinite Mile Award, AFAR Postdoctoral Fellowship, Glenn Foundation Fellowship and an NIA F30 training award
- Founded the nonprofit Longevity Global and co-founded Academics for the Future of Science

## Latest updates

- **2026-02** — NeuroAge Therapeutics closed seed funding to expand its AI brain-aging diagnostics.
- **2023-01** — NeuroAge named one of the top 10 companies to watch by Life Science Nation.

## Links

- Website: https://neuroagetx.com
- LinkedIn: http://www.linkedin.com/in/christin-glorioso-md-phd-39627719
- Twitter/X: https://x.com/drglorioso
- YouTube: https://youtu.be/_D1Vc9aC3nU

---

Profile page: https://yespress.io/christin-glorioso
Published by YesPress — https://yespress.io
Last updated: 2026-06-25